He has expertise in cytological and histological techniques and staining, and various molecular methods including ISH, PCR, NGS and advanced methods such as proteomics. His research area is translational oncology, from preclinical to clinical, with a particular focus on the microenvironment in solid tumours.
EDUCATION
PhD in Traslational Medicine
RESEARCH, TEACHING, or OTHER INTERESTS
Oncology, Histology, Immunology and Allergy, Genetics (clinical)
52
Scopus Publications
Scopus Publications
Glycolytic heterogeneity drives metabolic-targeted therapy in pancreatic ductal adenocarcinoma Ugo Chianese, Chiara Papulino, Gerardo Saggese, Ahmad Ali, Marianna Ciotola, Enza Lonardo, Mirko Cortese, Gregorio Favale, Annabella Di Mauro, Danila La Gioia, Valentina Golino, Eduardo Sommella, Pietro Campiglia, Renato Franco, Fortunato Ciardiello, Ferdinando De Vita, Vincenzo Carafa, Lucia Altucci, Rosaria Benedetti Signal Transduction and Targeted Therapy, 2026 Pancreatic ductal adenocarcinoma is traditionally characterized as a glycolytic tumor. However, the extent and clinical relevance of its metabolic heterogeneity remain poorly understood. In this study, we investigated whether glycolytic activity follows a consistent expression pattern across pancreatic ductal adenocarcinoma patients and explored how metabolic diversity influences therapeutic responses. Using spatial transcriptomics of ex vivo primary human pancreatic ductal adenocarcinoma specimens, along with single-cell and bulk RNA sequencing, we mapped glycolytic heterogeneity within the tumor microenvironment. Patient-derived cell models representing distinct glycolytic phenotypes were employed to assess metabolic profiles and responses to glycolytic pathway inhibition. A multiomics approach—including metabolomics, proteomics, and lipidomics—was integrated through a robust bioinformatics pipeline to identify pathway-specific variations. Our findings revealed pronounced glycolytic heterogeneity across pancreatic ductal adenocarcinoma tumors, with distinct transcriptional profiles that maintained cellular identity and spatial architecture. These glycolytic patterns are associated with clinical outcomes, suggesting their potential as prognostic indicators. Functional studies confirmed differential sensitivity to metabolic inhibitors in organoids and demonstrated their safety across models, supporting the therapeutic relevance of glycolytic stratification. Overall, this study reveals clinically significant metabolic heterogeneity in pancreatic ductal adenocarcinoma and proposes a glycolysis-based framework for patient stratification, which could guide personalized metabolic therapies and advance precision oncology in pancreatic cancer.
Emerging Genomic and Immunological Correlates Defining Oligometastatic Trajectories in Intermediate/High-Grade Soft-Tissue Sarcomas Alessandro Ottaiano, Francesco Sabbatino, Carmine Picone, Nadia Di Carluccio, Igino Simonetti, Annabella Di Mauro, Salvatore Tafuto Genes, 2026 Soft-tissue sarcomas (STSs) comprise a rare, heterogeneous group of mesenchymal malignancies in which histologic grade remains the strongest determinant of outcome, metastatic risk, and therapeutic strategy. Intermediate/high-grade STSs exhibit a pronounced propensity for early distant relapse, yet growing evidence indicates that metastatic behaviour is not uniform. Within this spectrum, an oligometastatic phenotype, characterised by a limited number of metastases, often confined to the lung, has emerged as a clinically and biologically distinct state associated with more indolent metastatic kinetics and improved survival when treated with aggressive local interventions. However, the criteria that define true oligometastatic STSs remain unsettled, and prospective evidence is lacking. Emerging molecular and immunological correlates provide a potential framework for biological triage. Low genomic complexity (low-risk CINSARC), a B-cell/TLS-rich tumour microenvironment, high immune-cytotoxic signatures, and persistently low or undetectable circulating tumour DNA (ctDNA) are each linked to reduced metastatic competence and may underpin oligometastatic trajectories. Conversely, high chromosomal instability, immunosuppressive microenvironments, and elevated ctDNA levels align with covertly polymetastatic biology despite limited radiographic disease. In this context, artificial intelligence and machinelearning approaches applied to computational genomics, immune profiling, imaging, and liquid-biopsy data offer a powerful strategy to integrate these multi-dimensional features and refine predictions of metastatic behaviour in STS. Oligometastatic STS therefore represents a biologically definable subset amenable to multimodal management integrating local ablative therapies, systemic agents, and immune-based strategies. Prospective, biomarker-stratified trials are needed to validate selection frameworks and optimise treatment sequencing in this evolving therapeutic space.
Modern Pathology-Driven Strategies in Neoadjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma: From Residual Tumor Quantification to Spatial and AI-Based Biomarkers Annabella Di Mauro, Rossella De Cecio, Saverio Simonelli, Margherita Cerrone, Rosalia Anna Rega, Maria Luisa Marciano, Monica Pontone, Imma D'arbitrio, Francesco Perri, Gerardo Ferrara Cancers, 2026 Neoadjuvant strategies in head and neck squamous cell carcinoma (HNSCC) are reshaping therapeutic paradigms by shifting emphasis from anatomical staging toward biology-driven response stratification. The transition from induction chemotherapy to immune checkpoint–based and combination regimens has transformed the perioperative setting into a translational platform that enables interrogation of tumor–immune interactions and clonal selection under therapeutic pressure prior to surgery. In this context, pathological response assessment has emerged as a robust surrogate endpoint, overcoming the limitations of radiologic evaluation, which often fails to capture immune-mediated pseudoprogression and spatially heterogeneous regression. Quantification of residual viable tumor (RVT) provides a reproducible metric of therapeutic efficacy, while characterization of immune-related regression beds, tertiary lymphoid structures, macrophage polarization states, and compartment-specific nodal responses offers mechanistic insight into tumor clearance and resistance evolution. Evidence from phase II trials, single-cell sequencing, spatial transcriptomics, and multiplex immune profiling supports the prognostic relevance of pathology-driven endpoints. Integration of digital pathology and artificial intelligence–assisted image analysis further enhances reproducibility and enables high-resolution mapping of residual disease and immune architecture. Within this modern oncologic framework, the neoadjuvant-treated specimen functions as a dynamic biomarker platform guiding response-adapted surgical strategies and biomarker-driven clinical trial design. This study was designed as a narrative review. A structured literature search was performed using PubMed and major oncology journals to identify relevant studies on pathology-driven response assessment in neoadjuvant-treated head and neck squamous cell carcinoma. The review focused on publications addressing histopathological response criteria, immune microenvironment remodeling, spatial profiling technologies, and computational pathology approaches.
Genomic profiling of a DICER1-wildtype thyroblastoma reveals AGK-BRAF fusion, EIF1AX duplication, and TERT promoter mutations: integrated genomic and pathway analysis Alberto Gualandi, Fernanda Picozzi, Annabella Di Mauro, Susi Pelotti, Imma D’Arbitrio, Pasquale De Luca, Lucia Cannella, Antonio Pizzolorusso, Alessandro Ottaiano, Annarita Peddio, Gerardo Ferrara, Salvatore Tafuto Frontiers in Endocrinology, 2026 Introduction Thyroblastoma is a rare and highly aggressive embryonal thyroid malignancy typically associated with DICER1 alterations. However, DICER1-wildtype cases remain poorly characterized at the molecular level. Methods We report a case of aggressive thyroblastoma in a 62-year-old male, negative for canonical DICER1 RNase IIIb mutations. Comprehensive genomic profiling was performed using Oxford Nanopore long-read sequencing, followed by integrative bioinformatic and pathway-level analyses. Results Molecular analysis revealed an alternative oncogenic signature characterized by an EIF1AX p.Lys3_Lys5dup duplication, TERT alterations (promoter C228T and coding p.C42R), and an AGK–BRAF fusion predicted to drive constitutive MAPK/ERK signaling. Functional enrichment analyses highlighted dysregulation of translational initiation, telomere maintenance, and mitogenic pathways, alongside potential immune-escape mechanisms linked to DUX4 activation. Clinically, the tumor exhibited a triphasic morphology, extensive locoregional infiltration, pulmonary metastases, and only transient response to chemotherapy. Discussion These findings expand the molecular spectrum of thyroblastoma beyond the canonical DICER1-driven paradigm and suggest that DICER1-wildtype cases may represent a distinct biological subgroup. The identification of alterations affecting TERT and MAPK pathways highlights potential therapeutic vulnerabilities and supports the clinical value of comprehensive genomic profiling in ultra-rare thyroid malignancies.
Genetic variants linked to type 2 diabetes in CDKN1B and TCF7L2 influence survival outcomes in metastatic colorectal cancer Raffaella Ruggiero, Alessandro Ottaiano, Madhura Tathode, Roberto Sirica, Annabella Di Mauro, Monica Ianniello, Nadia Petrillo, Massimiliano Berretta, Silvia Zappavigna, Amalia Luce, Michele Caraglia, Giovanni Savarese International Journal of Cancer, 2025 Evidence suggests that metastatic colorectal cancer patients with type 2 diabetes (T2D) experience a poorer prognosis in contrast to their non‐diabetic counterparts. Considering the multifactorial genetic nature of colon cancer development, we examined whether gene polymorphisms associated with T2D could affect the clinical outcome of metastatic colon cancer. Using in silico analysis, we evaluated gene variants linked to both T2D and colon cancer utilizing data from The Cancer Genome Atlas (TCGA). Subsequently, we assessed the prognostic relevance of polymorphisms in CCND2, CDKN1B, CDKN2A, CDKN2B, EML4, HNF1A, ID3, IGF1, IGF1R, IGF2, INHBA, INSR, IRS1, IRS2, and TCF7L2 in a cohort of 99 consecutive metastatic non‐diabetic colon cancer patients with favorable clinical conditions. Primary colon cancer DNA was sequenced using the TruSight Oncology 500 kit, followed by sequencing on an Illumina NovaSeq 6000 platform. Notably, patients carrying the CDKN1B p.V109G and TCF7L2 p.P370R polymorphisms exhibited significantly shorter median survivals compared to wild‐type counterparts, with adjusted hazard ratios (covariates: age, gender, metastatic extent, RAS/BRAF mutations, and response to therapy) of 2.28 (95% CI: 1.18–4.41) and 4.45 (95% CI: 1.26–15.70), respectively. Our findings provide scientific evidence of T2D genetic polymorphisms' involvement in determining the aggressiveness of metastatic colon cancer, identifying CDKN1B p.V109G and TCF7L2 p.P370R as novel unfavorable prognostic markers.
Towards Post-Genomic Oncology: Embracing Cancer Complexity via Artificial Intelligence, Multi-Targeted Therapeutics, Drug Repurposing, and Innovative Study Designs Annabella Di Mauro, Massimiliano Berretta, Mariachiara Santorsola, Gerardo Ferrara, Carmine Picone, Giovanni Savarese, Alessandro Ottaiano International Journal of Molecular Sciences, 2025 Recent advances in precision oncology have led to significant breakthroughs through the targeting of defined oncogenic drivers. However, the clinical efficacy of single-target therapies is increasingly constrained by the intrinsic complexity and adaptability of cancer. Solid tumors frequently arise from multifactorial oncogenic processes and adapt via diverse resistance mechanisms, ultimately limiting the durability of monotherapies. This review advocates for a paradigm shift toward multi-targeted, AI-enhanced strategies that harness high-throughput multi-omic data to inform the rational design of combination therapies. By leveraging artificial intelligence for drug discovery and repurposing, response prediction, and clinical trial optimization, the field of oncology is poised to transcend reductionist approaches and more fully address the biological intricacy of cancer.
Cardio–Renal and Systemic Effects of SGLT2i Dapagliflozin on Short-Term Anthracycline and HER-2-Blocking Agent Therapy-Induced Cardiotoxicity Vincenzo Quagliariello, Annabella Di Mauro, Gerardo Ferrara, Francesca Bruzzese, Giuseppe Palma, Antonio Luciano, Maria Laura Canale, Irma Bisceglia, Martina Iovine, Christian Cadeddu Dessalvi, Carlo Maurea, Matteo Barbato, Alessandro Inno, Massimiliano Berretta, Andrea Paccone, Alfredo Mauriello, Celeste Fonderico, Anna Chiara Maratea, Nicola Maurea Antioxidants, 2025 Anthracyclines and human epidermal growth factor receptor 2 (HER-2) inhibitors are cornerstone therapies for breast cancer but are associated with significant cardiotoxicity. While sodium–glucose cotransporter 2 (SGLT2) inhibitors such as dapagliflozin have demonstrated cardio–renal protective effects during anthracycline treatment, their efficacy in preventing cardiotoxicity from sequential anthracycline and HER-2 blockade remains poorly understood. This study investigates the cardioprotective role of dapagliflozin in a preclinical model of chemotherapy-induced cardiotoxicity. Female C57Bl/6 mice were divided into four groups and treated for 10 days as follows: (1) a normal control group receiving saline (sham); (2) a model control group receiving doxorubicin (2.17 mg/kg/day for 5 days) followed by HER-2-blocking monoclonal antibody (2.25 mg/kg/day for 5 days); (3) a dapagliflozin-only group (10 mg/kg/day via oral gavage); and (4) a treatment group receiving the combination of doxorubicin, HER-2 inhibitor, and dapagliflozin. Cardiac function was assessed using echocardiography (VEVO 2100). Biomarkers of myocardial injury and inflammation (NLRP3, MyD88, CXCR4, H-FABP, troponin-T, and cytokines) were quantified via ELISA and immunohistochemistry. Circulating markers such as mitofusin-2, cardiac myosin light chain, malondialdehyde (MDA), and 4-hydroxy-2-nonenal (4-HNE) were also measured. Dapagliflozin significantly preserved the ejection fraction and reduced both radial and longitudinal strain impairment in mice treated with the doxorubicin–HER-2 inhibitor combination (p < 0.001). Levels of myocardial NLRP3, MyD88, CXCR4, H-FABP, interleukin-1β, and troponin-T were significantly lower in the dapagliflozin-treated group compared to the chemotherapy-only group. Serum markers of oxidative stress and cardiac injury, including mitofusin-2, MDA, 4-HNE, BNP, and high-sensitivity C-reactive protein (hs-CRP), were also reduced by dapagliflozin treatment. Our findings demonstrate that dapagliflozin effectively mitigates early cardiac dysfunction and injury in a preclinical model of sequential doxorubicin and HER-2 inhibitor therapy.
A Rare Malignant Case of a Primary Pseudomyogenic Haemangioendothelioma of the Bone Annabella Di Mauro, Salvatore Tafuto, Lucia Cannella, Francesca Collina, Giovanni Neri, Ottavia Clemente, Imma D’Arbitrio, Francesca Ricci, Secondo Lastoria, Gerardo Ferrara, Annarosaria De Chiara Current Oncology, 2025 Pseudomyogenic haemangioendotheliomas (PMH) are exceedingly rare, mostly occurring in soft tissue, with malignant cases even more uncommon. In this report, we present a case of a 28-year-old male initially suspected of having a fibroblastic osteosarcoma of the right femur, which was then correctly diagnosed as a primary pseudomyogenic hemangioendothelioma of the bone with synchronous metastases to other skeletal segments. Molecular analysis through targeted RNA sequencing confirmed the correct diagnosis, revealing a fusion transcript ACTB::FOSB. To our knowledge, this is one of the few reported cases of suffering from multiple pathological fractures. The rapid skeletal progression and the onset of distant metastases in this case is highly unusual considering the typically indolent clinical course commonly reported in the literature for this tumor.
Negative Hyperselection in Metastatic Colorectal Cancer for First-Line Anti-EGFR Therapy: A Narrative Review Giuliana Ciappina, Enrica Toscano, Alessandro Ottaiano, Maurizio Capuozzo, Pierluigi Consolo, Enrica Maiorana, Patrizia Carroccio, Tindara Franchina, Antonio Ieni, Annabella Di Mauro, Massimiliano Berretta International Journal of Molecular Sciences, 2025 Colorectal cancer (CRC) remains a leading cause of cancer-related mortality, with metastatic disease posing significant therapeutic challenges. While anti-EGFR therapy has improved outcomes for patients with RAS and BRAF wild-type tumors, resistance remains a major hurdle, limiting treatment efficacy. The concept of negative hyperselection has emerged as a refinement of molecular profiling, identifying additional genomic alterations—such as HER2 and MET amplificationsand MAP2K1 mutations—that predict resistance to anti-EGFR agents. Studies incorporating these expanded assessments have demonstrated that nearly half of patients with RAS/BRAF wild-type tumors harbor alternative resistance biomarkers, underscoring the need for expanded selection criteria. Liquid biopsies, particularly circulating tumor DNA (ctDNA) analysis, have revolutionized precision oncology by providing a minimally invasive, real-time assessment of tumor dynamics. ctDNA-based hyperselection enables the detection of resistance-associated alterations, guiding treatment decisions with greater accuracy than conventional tissue biopsies. Recent trials support the predictive value of ctDNA-defined negative hyperselection, revealing superior outcomes for patients stratified through liquid biopsy. This narrative review explores the evolving role of molecular hyperselection in first-line anti-EGFR therapy, emphasizing the integration of ctDNA to refine patient selection, enhance therapeutic efficacy, and pave the way for personalized treatment strategies in metastatic CRC.
Treatments, prognostic factors, and genetic heterogeneity in advanced cholangiocarcinoma: A multicenter real-world study Alessandro Ottaiano, Mariachiara Santorsola, Anna Diana, Andrea Belli, Maria Luisa Lentini Graziano, Jessica Orefice, Renato Patrone, Annabella Di Mauro, Giosuè Scognamiglio, Fabiana Tatangelo, Mario De Bellis, Mauro Piccirillo, Francesco Fiore, Salvatore Stilo, Luca Tarotto, Marco Correra, Sara Di Lorenzo, Maurizio Capuozzo, Antonio Avallone, Lucrezia Silvestro, Antonella Bianco, Vincenza Granata, Piera Federico, Vincenzo Montesarchio, Bruno Daniele, Francesco Izzo, Guglielmo Nasti Cancer Medicine, 2024
Oligo-metastatic neoPlasms from the gastro-intestinal tract: iDentIfiCaTIon of cliNical and molecular drivers: the PREDICTION study Alessandro Ottaiano, Antonella De Luca, Mariachiara Santorsola, Giosuè Scognamiglio, Annabella Di Mauro, Paolo Chiodini, Matilde Lambiase, Alessandra Sacco, Antonella Petrillo, Vincenza Granata, Roberta Fusco, Edoardo Mercadante, Nicola Martucci, Giuseppe De Luca, Antonello La Rocca, Egidio Celentano, Anna Crispo, Piergiacomo Di Gennaro, Fabiana Tatangelo, Gerardo Ferrara, Francesco Izzo, Andrea Belli, Renato Patrone, Paolo Delrio, Daniela Rega, Silvia De Franciscis, Paolo Muto, Vincenzo Ravo, Rossella Di Franco, Valentina Borzillo, Sara Santagata, Giuseppina Rea, Daniela Castaldo, Ugo Pace, Gianfranco De Feo, Stefania Scala, Guglielmo Nasti, Nicola Normanno BMC Cancer, 2023
BRAF p.V600E mutation as a molecular boundary between genuine oligo-repeated and poly-metastatic disease in colorectal cancer Alessandro Ottaiano, Mariachiara Santorsola, Luisa Circelli, Monica Ianniello, Marika Casillo, Nadia Petrillo, Francesco Sabbatino, Marco Cascella, Francesco Perri, Maurizio Capuozzo, Vittorio Albino, Vincenza Granata, Francesco Izzo, Annabella Di Mauro, Massimiliano Berretta, Raffaella Ruggiero, Oreste Gualillo, Roberto Sirica, Guglielmo Nasti, Giovanni Savarese Neoplasia United States, 2023
Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis Viola Melone, Annamaria Salvati, Domenico Palumbo, Giorgio Giurato, Giovanni Nassa, Francesca Rizzo, Luigi Palo, Alessandro Giordano, Mariarosaria Incoronato, Mario Vitale, Caterina Mian, Immacolata Di Biase, Stefano Cristiano, Viviana Narciso, Monica Cantile, Annabella Di Mauro, Fabiana Tatangelo, Salvatore Tafuto, Roberta Modica, Claudia Pivonello, Marco Salvatore, Annamaria Colao, Alessandro Weisz, Roberta Tarallo Journal of Translational Medicine, 2022
Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy Caterina Vianello, Veronica Cocetta, Daniela Catanzaro, Gerald W Dorn, Angelo De Milito, Flavio Rizzolio, Vincenzo Canzonieri, Erika Cecchin, Rossana Roncato, Giuseppe Toffoli, Vincenzo Quagliariello, Annabella Di Mauro, Simona Losito, Nicola Maurea, Scaffa Cono, Gabriele Sales, Luca Scorrano, Marta Giacomello, Monica Montopoli Cell Death and Disease, 2022
In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies Caterina Ieranò, Dario Righelli, Crescenzo D'Alterio, Maria Napolitano, Luigi Portella, Giuseppina Rea, Federica Auletta, Sara Santagata, Anna Maria Trotta, Giuseppe Guardascione, Federica Liotti, Nella Prevete, Piera Maiolino, Antonio Luciano, Antonio Barbieri, Annabella Di Mauro, Cristin Roma, Riziero Esposito Abate, Fabiana Tatangelo, Roberto Pacelli, Nicola Normanno, Rosa Marina Melillo, Stefania Scala Journal for Immunotherapy of Cancer, 2022
Metastatic colorectal cancer and type 2 diabetes: prognostic and genetic interactions Alessandro Ottaiano, Luisa Circelli, Mariachiara Santorsola, Giovanni Savarese, Daniela Fontanella, Valerio Gigantino, Annabella Di Mauro, Maurizio Capuozzo, Silvia Zappavigna, Angela Lombardi, Francesco Perri, Marco Cascella, Vincenza Granata, Maurizio Capuozzo, Guglielmo Nasti, Michele Caraglia Molecular Oncology, 2022
MHC-Optimized Peptide Scaffold for Improved Antigen Presentation and Anti-Tumor Response Maria Tagliamonte, Angela Mauriello, Beatrice Cavalluzzo, Concetta Ragone, Carmen Manolio, Antonio Luciano, Antonio Barbieri, Giuseppe Palma, Giosuè Scognamiglio, Annabella Di Mauro, Maurizio Di Bonito, Maria Lina Tornesello, Franco M. Buonaguro, Luigi Vitagliano, Andrea Caporale, Menotti Ruvo, Luigi Buonaguro Frontiers in Immunology, 2021
Prospective evaluation of radiotherapy-induced immunologic and genetic effects in colorectal cancer oligo-metastatic patients with lung-limited disease: The prelude-1 study Alessandro Ottaiano, Angela Petito, Mariachiara Santorsola, Valerio Gigantino, Maurizio Capuozzo, Daniela Fontanella, Rossella Di Franco, Valentina Borzillo, Sergio Buonopane, Vincenzo Ravo, Esmeralda Scipilliti, Giuseppe Totaro, Marcello Serra, Gianluca Ametrano, Roberta Penta, Fabiana Tatangelo, Giosuè Scognamiglio, Annabella Di Mauro, Maurizio Di Bonito, Maria Napolitano, Stefania Scala, Giuseppina Rea, Sara Santagata, Angela Lombardi, Anna Grimaldi, Carlo Caputo, Anna Crispo, Egidio Celentano, Gianfranco De Feo, Luisa Circelli, Giovanni Savarese, Raffaella Ruggiero, Francesco Perri, Vincenza Granata, Gerardo Botti, Michele Caraglia, Guglielmo Nasti, Paolo Muto Cancers, 2021
Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol Alessandro Ottaiano, Stefania Scala, Mariachiara Santorsola, Anna Maria Trotta, Crescenzo D’Alterio, Luigi Portella, Ottavia Clemente, Anna Nappi, Nicoletta Zanaletti, Alfonso De Stefano, Antonio Avallone, Vincenza Granata, Carmen Notariello, Amalia Luce, Angela Lombardi, Carmine Picone, Antonella Petrillo, Francesco Perri, Fabiana Tatangelo, Annabella Di Mauro, Vittorio Albino, Francesco Izzo, Daniela Rega, Ugo Pace, Massimiliano Di Marzo, Paolo Chiodini, Gianfranco De Feo, Paola Del Prete, Gerardo Botti, Paolo Delrio, Michele Caraglia, Guglielmo Nasti Therapeutic Advances in Medical Oncology, 2021
Evolution of mutational landscape and tumor immune-microenvironment in liver oligo-metastatic colorectal cancer Alessandro Ottaiano, Michele Caraglia, Annabella Di Mauro, Gerardo Botti, Angela Lombardi, Jerome Galon, Amalia Luce, Luigi D’Amore, Francesco Perri, Mariachiara Santorsola, Fabienne Hermitte, Giovanni Savarese, Fabiana Tatangelo, Vincenza Granata, Francesco Izzo, Andrea Belli, Stefania Scala, Paolo Delrio, Luisa Circelli, Guglielmo Nasti Cancers, 2020
Study of ras mutations’ prognostic value in metastatic colorectal cancer: Storia analysis Alessandro Ottaiano, Nicola Normanno, Sergio Facchini, Antonino Cassata, Anna Nappi, Carmela Romano, Lucrezia Silvestro, Alfonso De Stefano, Anna Maria Rachiglio, Cristin Roma, Monica R. Maiello, Stefania Scala, Paolo Delrio, Fabiana Tatangelo, Annabella Di Mauro, Gerardo Botti, Antonio Avallone, Guglielmo Nasti Cancers, 2020
Genetic trajectory and immune microenvironment of lung-specific oligometastatic colorectal cancer Alessandro Ottaiano, Luisa Circelli, Angela Lombardi, Stefania Scala, Nicola Martucci, Jerome Galon, Manuela Buonanno, Giosuè Scognamiglio, Gerardo Botti, Fabienne Hermitte, Giovanni Savarese, Luigi D’Amore, Fabiana Tatangelo, Annabella Di Mauro, Giuseppina Liguori, Anna Maria Trotta, Maria Napolitano, Monica Capozzi, Salvatore Tafuto, Francesco Perri, Antonello La Rocca, Michele Caraglia, Guglielmo Nasti Cell Death and Disease, 2020
Evaluation of MGMT Gene Methylation in Neuroendocrine Neoplasms Rosa Della Monica, Mariella Cuomo, Roberta Visconti, Annabella di Mauro, Michela Buonaiuto, Davide Costabile, Giulia De Riso, Teodolinda Di Risi, Elia Guadagno, Roberto Tafuto, Sabrina Lamia, Alessandro Ottaiano, Paolo Cappabianca, Maria Laura Del Basso de Caro, Fabiana Tatangelo, Juergen Hench, Stephan Frank, Salvatore Tafuto, Lorenzo Chiariotti Oncology Research, 2020
Distributed genomic compression in mapreduce paradigm Pasquale De Luca, Stefano Fiscale, Luca Landolfi, Annabella Di Mauro Lecture Notes in Computer Science Including Subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics, 2019
